145 related articles for article (PubMed ID: 33592148)
1. Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A
Markert C; Thoma G; Srinivas H; Bollbuck B; Lüönd RM; Miltz W; Wälchli R; Wolf R; Hinrichs J; Bergsdorf C; Azzaoui K; Penno CA; Klein K; Wack N; Jäger P; Hasler F; Beerli C; Loetscher P; Dawson J; Wieczorek G; Numao S; Littlewood-Evans A; Röhn TA
J Med Chem; 2021 Feb; 64(4):1889-1903. PubMed ID: 33592148
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors.
Röhn TA; Numao S; Otto H; Loesche C; Thoma G
Expert Opin Drug Discov; 2021 Dec; 16(12):1483-1495. PubMed ID: 34191664
[TBL] [Abstract][Full Text] [Related]
3. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
4. The development of novel LTA
Low CM; Akthar S; Patel DF; Löser S; Wong CT; Jackson PL; Blalock JE; Hare SA; Lloyd CM; Snelgrove RJ
Sci Rep; 2017 Mar; 7():44449. PubMed ID: 28303931
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
[TBL] [Abstract][Full Text] [Related]
6. LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial.
Loesche C; Picard D; Van Hoorick B; Schuhmann I; Jäger P; Klein K; Schuhler C; Thoma G; Markert C; Poller B; Zamurovic N; Weiss HM; Otto H; Fink M; Röhn TA
Clin Transl Sci; 2024 Feb; 17(2):e13724. PubMed ID: 38407540
[TBL] [Abstract][Full Text] [Related]
7. Leukotriene A4 hydrolase as a target for cancer prevention and therapy.
Chen X; Wang S; Wu N; Yang CS
Curr Cancer Drug Targets; 2004 May; 4(3):267-83. PubMed ID: 15134534
[TBL] [Abstract][Full Text] [Related]
8. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase.
Fourie AM
Curr Opin Investig Drugs; 2009 Nov; 10(11):1173-82. PubMed ID: 19876785
[TBL] [Abstract][Full Text] [Related]
9. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
10. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
11. Structure-Guided Elaboration of a Fragment-Like Hit into an Orally Efficacious Leukotriene A4 Hydrolase Inhibitor.
Thoma G; Miltz W; Srinivas H; Penno CA; Kiffe M; Gajewska M; Klein K; Evans A; Beerli C; Röhn TA
J Med Chem; 2024 Mar; 67(6):5093-5108. PubMed ID: 38476002
[TBL] [Abstract][Full Text] [Related]
12. Thermodynamic properties of leukotriene A
Wittmann SK; Kalinowsky L; Kramer JS; Bloecher R; Knapp S; Steinhilber D; Pogoryelov D; Proschak E; Heering J
Bioorg Med Chem; 2016 Nov; 24(21):5243-5248. PubMed ID: 27651294
[TBL] [Abstract][Full Text] [Related]
13. Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods.
Qin R; Wang H; Yan A
SAR QSAR Environ Res; 2021 May; 32(5):411-431. PubMed ID: 33896285
[TBL] [Abstract][Full Text] [Related]
14. A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.
Poras H; Duquesnoy S; Fournié-Zaluski MC; Ratinaud-Giraud C; Roques BP; Ouimet T
Anal Biochem; 2013 Oct; 441(2):152-61. PubMed ID: 23851339
[TBL] [Abstract][Full Text] [Related]
15. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.
Davies DR; Mamat B; Magnusson OT; Christensen J; Haraldsson MH; Mishra R; Pease B; Hansen E; Singh J; Zembower D; Kim H; Kiselyov AS; Burgin AB; Gurney ME; Stewart LJ
J Med Chem; 2009 Aug; 52(15):4694-715. PubMed ID: 19618939
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Leukotriene A
Wu X; Sun AR; Crawford R; Xiao Y; Wang Y; Prasadam I; Mao X
Cartilage; 2024 Jun; 15(2):184-194. PubMed ID: 37086004
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Amino Alcohols as Highly Potent, Selective, and Orally Efficacious Inhibitors of Leukotriene A4 Hydrolase.
Thoma G; Markert C; Lueoend R; Miltz W; Spanka C; Bollbuck B; Wolf RM; Srinivas H; Penno CA; Kiffe M; Gajewska M; Bednarczyk D; Wieczorek G; Evans A; Beerli C; Röhn TA
J Med Chem; 2023 Dec; 66(23):16410-16425. PubMed ID: 38015154
[TBL] [Abstract][Full Text] [Related]
18. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin.
Chen X; Li N; Wang S; Wu N; Hong J; Jiao X; Krasna MJ; Beer DG; Yang CS
J Natl Cancer Inst; 2003 Jul; 95(14):1053-61. PubMed ID: 12865451
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of Leukotriene A4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury.
Li X; Xie M; Lu C; Mao J; Cao Y; Yang Y; Wei Y; Liu X; Cao S; Song Y; Peng J; Zhou Y; Jiang Q; Lin G; Qin S; Qi M; Hou M; Liu X; Zhou H; Yang G; Yang C
Eur J Med Chem; 2020 Oct; 203():112614. PubMed ID: 32679453
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, docking, cytotoxicity, and LTA
El-Naggar MH; Mira A; Abdel Bar FM; Shimizu K; Amer MM; Badria FA
Bioorg Med Chem; 2017 Feb; 25(3):1277-1285. PubMed ID: 28065501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
